Related Experiment Video
Updated: Aug 17, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia
Abstract:
Polymorphisms in carcinogen- and drug-metabolizing enzymes may increase the risk of acute myeloid leukemia (AML) and may influence prognosis. We report that the polymorphic variant of the cytochrome P450 CYP1A1*2A, present in 11.3% of patients, is an independent unfavorable prognostic factor for failure-free and overall survival in patients with AML.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase